MorphoSys AG and Heptares Therapeutics Ltd have entered into a collaboration to generate candidate antibody therapeutics targeting G protein-coupled receptors (GPCRs). The disease targets will be proposed by MorphoSys. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
